Evidence map›Paper›PMID 36810521›Full record

ArticleAntibodies (Basel, Switzerland)2023

Bioprocess Development and Characterization of a

Aaron T Wecksler, Victor Lundin, Ambrose J Williams, Karthik Veeravalli, Dorothea E Reilly, Sung-Hye Grieco

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aaron T WeckslerProtein Analytical Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.ORCID 0000-0002-6050-0926
Victor LundinProtein Analytical Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.
Ambrose J WilliamsPurification Development, Genentech Inc., South San Francisco, CA 94080, USA.
Karthik VeeravalliCell Culture and Bioprocess Operations, Genentech Inc., South San Francisco, CA 94080, USA.
Dorothea E ReillyCell Culture and Bioprocess Operations, Genentech Inc., South San Francisco, CA 94080, USA.
Sung-Hye GriecoCell Culture and Bioprocess Operations, Genentech Inc., South San Francisco, CA 94080, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) are highly efficacious therapeutics; however, due to their large, dynamic nature, structural perturbations and regional modifications are often difficult to study. Moreover, the homodimeric, symmetrical nature of mAbs makes it difficult to elucidate which heavy chain (HC)-light chain (LC) pairs are responsible for any structural changes, stability concerns, and/or site-specific modifications. Isotopic labeling is an attractive means for selectively incorporating atoms with known mass differences to enable identification/monitoring using techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR). However, the isotopic incorporation of atoms into proteins is typically incomplete. Here we present a strategy for incorporating

Indexed as

13C-celtone13C-labeled glucoseambr250 bioreactorsbiotherapeutic proteinsknob-into-holeprotein isotopic labeling

Identifiers

PMID36810521
PMCPMC9944054
OpenAlexW4320728127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.